Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 8/20 | 0.42 |
| ▸ | CCR3 | P51677 | 8/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406049 | 0.86 | GPR119 (0.48) | GPR119HRH3ALKNPBWR1MCHR1 | |
| SCHEMBL3282383 | 0.85 | GPR119 (0.59) | GPR119HRH3NPBWR1MCHR1HRH1 | |
| SCHEMBL2585041 | 0.83 | FFAR4 (0.53) | GPR119HRH3HRH1CCR3CHEK2 | |
| SCHEMBL5462103 | 0.81 | GPR119 (0.58) | GPR119HRH3NPBWR1MCHR1HRH1 | |
| SCHEMBL5194646 | 0.80 | CCR3 (0.47) | GPR119HRH3HRH1CCR3KCNH2 | |
| SCHEMBL4720822 | 0.79 | HRH1 (0.62) | GPR119HRH3HRH1CCR3KCNH2 | |
| SCHEMBL3283465 | 0.79 | GPR119 (0.64) | GPR119HRH3ALKNPBWR1MCHR1 | |
| SCHEMBL4140781 | 0.77 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL20570284 | 0.76 | GPR119 (0.57) | GPR119HRH3ALKNPBWR1MCHR1 | |
| SCHEMBL648469 | 0.76 | HPGD (0.41) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR1, CCR3, CCRL2 | GPR119 833/4885HRH3 24/4885ALK 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.